Sanofi and Orano join forces to develop next-generationradioligand medicines
Press Release – Paris, October 17, 2024. Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise in the fight against rare cancers and further accelerate the development of next-generation radioligand medicines. Building on the expertise and radioligand pipeline of Orano Med, Sanofi and Orano will … Continue reading Sanofi and Orano join forces to develop next-generationradioligand medicines
